Digital Pathology & AI Diagnostics Patent Landscape
Digital Pathology & AI Diagnostics Patent Landscape in 2026
The digital pathology and AI diagnostics space is concentrated, with the top five filers accounting for 38% of the hundred largest filers’ combined output and Ventana Medical Systems holding the leading position. The field has reached maturity — annual volume peaked in 2022 and has since plateaued — while image-processing and healthcare-informatics branches continue to dominate the technology mix.
Ventana leads a concentrated but multi-tier field
These five account for 38% of the hundred largest filers’ combined total, signalling meaningful concentration at the top.
A clear tier gap separates the top four from the rest: the fifth-ranked applicant holds fewer than a quarter of the leader’s count, and ranks six through twenty are closely bunched between 68 and 163 patent families. This structure leaves room for focused challengers but makes displacement of the top two or three difficult without a step-change in filing strategy.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Ventana Medical Systems Inc. | 693 | |
| 2 | Paige AI Inc. | 507 | |
| 3 | Fujifilm Corporation | 438 | |
| 4 | Koninklijke Philips NV | 413 | |
| 5 | Siemens Healthineers AG | 163 | |
| 6 | F HOFFMANN LA ROCHE & CO AG | 157 | |
| 7 | Leica Biosystems Imaging Inc. | 146 | |
| 8 | Arch Development Corporation | 127 | |
| 9 | Sony Group Corporation | 126 | |
| 10 | Memorial Sloan Kettering Cancer Center | 115 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 11 | GE Precision Healthcare LLC | 113 | |
| 12 | Genentech Inc. | 104 | |
| 13 | Siemens Medical Solutions USA Inc. | 104 | |
| 14 | Samsung Electronics Co., Ltd. | 97 | |
| 15 | University of Chicago | 95 | |
| 16 | University of Pittsburgh | 95 | |
| 17 | Canon Inc. | 90 | |
| 18 | Merative US LP | 79 | |
| 19 | F. Hoffmann-La Roche Inc. | 76 | |
| 20 | Lunit Inc. | 68 |
Ventana’s sustained lead, combined with Paige AI’s large and AI-native portfolio, suggests that the leading positions reflect both legacy instrument-side depth and newer algorithm-focused coverage. Entrants seeking differentiation must navigate established IP in core image-analysis methods.
Filings from approximately 2024 onward are likely under-counted due to standard patent-publication lag; apparent volume in those years should not be read as a demand-side signal. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Volume peaked in 2022; image-processing IP dominates the technology mix
The filing trend and technology composition together show a field that expanded rapidly through 2022, has since plateaued near that peak, and remains anchored in image-data processing with healthcare informatics as a strong secondary branch.
Annual filing trend
Annual filings grew from 332 in 2017 to a peak of 907 in 2022, then eased to 780 in 2023. Figures for 2024–2026 reflect publication lag and should be treated as lower bounds, not a continuing decline. The multi-year trajectory is still net-positive relative to 2017 but the field is no longer in rapid-growth mode.
↗ Hover for values · click a bar to ask EurekaTechnology composition
G06T (image data processing and generation) is by far the dominant branch, reflecting the centrality of whole-slide image analysis. G16H (healthcare informatics) and G06V (image and video recognition) form a strong second tier, while A61B (diagnosis and surgery) and G06N (AI model computing) add clinical and algorithmic depth. Lower-count branches such as G01N (material analysis) and G02B (optical elements) represent comparatively under-served adjacencies.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Hybrid modular pathology archive scanning
Methods and systems are provided for optimizing the digital scanning of pathology slides in a transportable lab. A computing device-implemented method is described for receiving a plurality of pathology slides in the transportable lab, sorting the plurality of pathology slides based upon pathology slide condition to determine which of a plurality of… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Computer-aided diagnosis system for medical use | 726 |
| 2 | Computer-assisted method and apparatus for analysi… | 592 |
| 3 | System and method for three-dimensional image rend… | 470 |
| 4 | Methods and systems for content processing | 459 |
| 5 | Methods for improving the accuracy in differential… | 447 |
| 6 | Object and spatial level quantitative image analysis | 416 |
| 7 | Lung nodule detection and classification | 389 |
| 8 | System and method of computer-aided detection | 378 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the competitive structure means for R&D investment
Four lenses — maturity, concentration, collaboration, and geography — shape how new entrants and incumbents should allocate effort in this space.
Field has plateaued near its 2022 peak
The lifecycle stage is Maturity: annual filings peaked at 907 in 2022 and have plateaued near that level rather than continuing to climb. This signals that foundational methods are well-covered and incremental improvement patents are crowding the core branches. R&D investment in adjacent or cross-disciplinary branches is more likely to yield defensible white space than further filing in dominant image-processing classes.
Lifecycle: MatureTop four hold disproportionate share; tier-two is competitive
The top five filers account for 38% of the hundred largest filers’ combined output, with a pronounced gap after rank four. Ventana, Paige AI, Fujifilm, and Philips collectively anchor broad portfolios spanning image processing, healthcare informatics, and clinical diagnosis. The tier below rank five — with counts between 68 and 163 patent families — is closely contested and represents the most realistic entry point for challengers seeking to establish a ranked position.
Concentration: HighRoche-Ventana axis dominates co-filing; MSK cluster active in oncology
The most active co-filing relationship is between Ventana Medical Systems and F. Hoffmann-La Roche (78 joint families), reflecting their parent-subsidiary commercial alignment. F. Hoffmann-La Roche also co-files with Hoffmann-La Roche (28 families) and Genentech (16 families), forming a tightly integrated Roche group cluster. Separately, Memorial Sloan Kettering Cancer Center co-files with Memorial Hospital for Cancer and Allied Diseases and with Sloan Kettering Institute for Cancer Research (23 families each), indicating an academic-clinical oncology network. Ventana and Providence Health Services Oregon show a smaller but notable 11-family collaboration, pointing to clinical deployment partnerships.
Ecosystem: ClusteredUS-dominant; Europe and PCT follow; Asia underweighted relative to output
The United States leads in patent records by a wide margin, followed by Europe (EPO), WIPO (PCT), and China. India and Japan represent meaningful secondary markets. The relatively limited presence in South Korea and Taiwan is notable given both jurisdictions’ diagnostic imaging manufacturing capacity. Applicants targeting global freedom-to-operate should prioritize US, EP, and PCT filings, with China and India as increasingly important secondary validations.
Geography: US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Ventana Medical Systems Inc. | F. Hoffmann-La Roche Ltd. | 78 |
| F. Hoffmann-La Roche Ltd. | Hoffmann-La Roche AG | 28 |
| Ventana Medical Systems Inc. | Hoffmann-La Roche AG | 23 |
| Memorial Sloan Kettering Cancer Center | Memorial Hospital for Cancer and Allied Diseases | 23 |
| Memorial Sloan Kettering Cancer Center | Sloan Kettering Institute for Cancer Research | 23 |
| Ventana Medical Systems Inc. | Genentech Inc. | 21 |
| Koninklijke Philips NV | Philips Intellectual Property & Standards GmbH | 21 |
| F. Hoffmann-La Roche Ltd. | Roche Diagnostics GmbH | 18 |
| F. Hoffmann-La Roche Ltd. | Genentech Inc. | 16 |
| Ventana Medical Systems Inc. | Providence Health & Services (Oregon) | 11 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Ventana anchors the field; Paige AI leads among AI-native challengers
The top two applicants differ markedly in portfolio character: Ventana’s depth spans traditional image analysis, while Paige AI’s portfolio is weighted toward healthcare informatics and clinical AI inference. Both are growing or stable in recent filings, setting them apart from several large incumbents whose recent momentum has eased.
Ventana Medical Systems
Ventana holds 693 patent families — the largest portfolio in the ranking — with primary emphasis on image data processing and generation (G06T 7), image and video recognition (G06V 10), and data recognition and presentation (G06K 9). Recent filing momentum is positive at +17%, distinguishing Ventana from several incumbent players whose activity has declined. Its heaviest co-filing ties are with F. Hoffmann-La Roche and Genentech, reinforcing its position within the broader Roche diagnostics ecosystem.
families: 693Paige AI
Paige AI holds 507 patent families and leads among AI-native entrants, with its portfolio concentrated in healthcare informatics (G16H 30 and G16H 50) alongside image data processing (G06T 7). This informatics-heavy profile distinguishes it from instrument-rooted incumbents. Recent filing trend is slightly negative at –5%, likely reflecting publication lag in the most recent period rather than a strategic pullback, given the scale of its recent-period output of 230 families.
families: 507| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Ventana Medical Systems Inc. | 154 | ▲ +17% |
| Paige AI Inc. | 230 | ▬ -5% |
| Fujifilm Corporation | 191 | ▲ +14% |
| Koninklijke Philips NV | 34 | ▼ -57% |
| F. Hoffmann-La Roche Ltd. | 33 | ▼ -13% |
| Sony Group Corporation | 27 | ▼ -50% |
| Siemens Healthineers AG | 47 | ▼ -11% |
| Leica Biosystems Imaging Inc. | 24 | ▼ -37% |
Under-served branches adjacent to the dominant image-processing core
Several IPC classes appear at comparatively low share relative to the dominant G06T cluster. Two stand out as having both plausible technical value and a realistic entry path for teams already working in computational pathology.
G02B · Optical elements and systems
With 305 patent records and roughly 1% share among the top IPC classes, optical elements and systems is sparsely covered relative to the software-heavy core. Computational pathology increasingly depends on high-NA slide scanning, hyperspectral illumination, and light-sheet microscopy — hardware layers where IP is thin. Teams with expertise in optical engineering or microscopy optics could establish defensible positions in scanning hardware design, adaptive illumination, or lens-array architectures that feed directly into downstream AI pipelines.
Search this in Eureka →G16B · Bioinformatics
G16B (bioinformatics) carries 143 patent records — among the lowest of the clinically relevant branches — despite growing interest in integrating genomic, transcriptomic, and spatial-omics data with morphological image features. Multi-modal AI models that jointly reason over histology and molecular profiles represent a technically plausible and commercially relevant direction. The low current filing density suggests that teams developing cross-modal diagnostic algorithms could secure meaningful coverage before this sub-field attracts heavier incumbent attention.
Search this in Eureka →How leaders differ across technology routes
Strength of each leader across the main technology routes.
| Player | G06T 7 · Image data processing & generation | G16H 30 · Healthcare informatics | G06V 10 · Image/video recognition | G06K 9 · Data recognition & presentation | G16H 50 · Healthcare informatics |
|---|---|---|---|---|---|
| Ventana Medical Systems Inc. | Strong · 531 | Moderate · 121 | Moderate · 209 | Moderate · 190 | Emerging · 59 |
| Paige AI Inc. | Strong · 344 | Strong · 299 | Moderate · 139 | Moderate · 78 | Strong · 223 |
| Fujifilm Corporation | Strong · 244 | Strong · 253 | Moderate · 81 | Emerging · 36 | Moderate · 54 |
| Koninklijke Philips NV | Strong · 292 | Moderate · 104 | Moderate · 66 | Moderate · 84 | Emerging · 55 |
| F. Hoffmann-La Roche Ltd. | Strong · 133 | Absent | Moderate · 41 | Moderate · 38 | Absent |
| Memorial Sloan Kettering Cancer Center | Strong · 100 | Absent | Strong · 73 | Absent | Absent |
| Leica Biosystems Imaging Inc. | Strong · 89 | Moderate · 35 | Absent | Moderate · 34 | Absent |
Frequently asked questions
The corpus in scope contains 6,146 patent families spanning digital pathology and AI diagnostics globally.
Ventana Medical Systems holds the largest portfolio with 693 patent families, ahead of Paige AI (507), Fujifilm (438), Koninklijke Philips (413), and Siemens Healthineers (163).
The field is assessed as mature. Annual filings peaked at 907 in 2022 and have plateaued near that level. Figures for 2024–2026 are likely under-counted due to publication lag and should not be interpreted as a further decline.
Image data processing and generation (G06T) is the dominant branch, followed by healthcare informatics (G16H), image and video recognition (G06V), clinical diagnosis and surgery (A61B), and AI model computing (G06N).
The United States leads, followed by Europe (EPO), WIPO (PCT), China, India, and Japan. Applicants targeting comprehensive global protection should prioritize US, EP, and PCT filings, with China and India as key secondary markets.
Optical elements and systems (G02B, ~1% share) and bioinformatics (G16B, 143 patent records) are comparatively sparse relative to the dominant image-processing core and carry plausible technical and commercial value for teams entering the space.
Ready to map your own digital pathology landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.